Prostate Cancer Therapeutics Availability Has Increased In the Market Due To Rise in Focus on Targeted Drug Development
The increasing focus on targeted drug development and favorable regulatory policies have resulted in an increase in the number of prostate cancer therapeutics available. Some men may benefit from hormonal therapy in combination with radiation or surgery. Newer forms of hormone therapy are increasingly being used in advanced disease and have shown some promise. With the population aging rapidly, incidences of the disease are expected to increase.
However,
there are some limitations with these therapies. For example, some doctors
suspect they may have missed the high-grade cancer. As a result, they may opt
for radical surgery or radiation. However, this may be overkill for patients
with low-grade cancer. MRI-targeted biopsy is a new technique developed by NCI
scientists. This technique uses computer technology to fuse ultrasound and MRI
images to pinpoint areas of possible cancer. It is not currently practical to
use real-time guidance for prostate biopsy, however, it enables doctors to
conduct a biopsy of suspected cancer regions.
The
neuroendocrine cells present in the prostate exhibit distinct morphologic
features, including those of neurons. Inhibiting the activity of AR has been
shown to promote the differentiation of cancer cells. These agents may have
different effects on prostate cancer stem cells, which are thought to be
responsible for the progression of the disease. The effectiveness of HDACIs is
largely dependent on the specificity of the treatment. However, the potential
for neuroendocrine therapies is significant.
Despite
significant progress in the management of prostate cancer, many patients still
fail to respond to the standard agents. Thus, new molecular targets for Prostate
Cancer Therapeutics are necessary for better patient outcomes.
Activation of small GTPases (SGLTs) is a key aspect of most of the upregulated
receptors in prostate cancer. It has the potential to be an important
therapeutic intervention for advanced prostate cancer patients. It has also
shown promise in reducing prostate cancer burden. In March 2022, Novatris
Pluvicto received approval from US Food and Drug Administration as a targeted
radioligand therapy for treating progressive PSMA-positive metastatic
castration –resistant prostate cancer.
Comments
Post a Comment